Install
Pharmaphorum is an online publication on a mission to educate, inform, engage, and connect pharmaceutical industry leaders and to equip them to thrive in healthcare’s evolving digital future. Pharmaphorum is an online publication seeking to educate, inform, engage, & connect pharmaceutical industry leaders to thrive in
- 328articles · 90d
- 2+ day agolatest article
- Jun 15, 2026earliest in window
- 66%with images
- 360avg words
- Medical 250
- Health & Wellness 226
- Health 163
- Economy, Business & Finance 115
- Business & Industrial 88
- Finance & Business 54
- Science & Technology 36
- Science & Nature 16
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Pharma’s most expensive question is the last one asked
2+ day, 22+ hour ago (403+ words) Pharmaceutical firms are making an expensive mistake. They develop a drug, see it through clinical trials, and only then pause to ask whether it will secure reimbursement. But by then, capital has already been committed, and the drug has already…...
Brainomix AI lends weight to Endeavor Bio's IPF trial data
3+ day, 21+ hour ago (565+ words) An AI-powered imaging tool developed by Brainomix has been used to enrich data from a phase 2a trial of Endeavor BioMedicines' hedgehog pathway inhibitor taladegib, in development for idiopathic pulmonary fibrosis (IPF). The post hoc analysis of the study showed that…...
Scientists and algorithms: Finding the right balance in modern drug development
3+ day, 22+ hour ago (441+ words) Every few years, drug development goes through a moment where a new technology promises to change everything. Artificial intelligence is having that moment now. Unlike some previous waves of hype, this one is grounded in something real, but only if…...
Sandoz says it is entering "golden decade" in biosimilars
4+ day, 18+ hour ago (563+ words) Aerial view of Sandoz' drug substance facility in Lendava, Slovenia, part of a $1bn European hub for biosimilar development and production. Sandoz has told investors that it intends to double its net sales between 2025 and 2035, and sees a pivot towards biosimilars…...
AI in clinical trials: Building better trials before they start
4+ day, 20+ hour ago (809+ words) Drug development is an inherently risky endeavour, with the average probability of approval for a drug entering Phase I studies now sitting at just 6.7%. While much of this can be attributed to lack of efficacy, factors such as poor clinical…...
Cyber resilience: Protecting tomorrow's therapies before they reach tomorrow's patients
5+ day, 19+ hour ago (1068+ words) The life sciences sector has never been more innovative. Every year, hundreds of new companies are founded around promising therapies, diagnostics, medical technologies, and AI-enabled healthcare platforms. Many begin life with a handful of employees, modest operating budgets, and an…...
Women – and pharma – in AI: Where are we now?
1+ week, 1+ day ago (824+ words) This June marked the third such Women in AI event, taking place at a time when AI in medicine has progressed from pilot to infrastructure. Guest female speakers included: Dr Anushka Patchava, chief clinical & innovation officer, Cignpost; Nora Lamoudi-Sutcliffe, senior…...
One year later, EVERSANA plans to go beyond the AI agency
1+ week, 1+ day ago (782+ words) EVERSANA CEO Mark Thierer speaks at the EVERSANA-Google event in New York City last week. Editor's Note: pharmaphorum is an editorially independent publication owned by EVERSANA. It’s been one year since EVERSANA rolled out its ambitious AI agency in partnership…...
Navigating Europe's AI regulatory labyrinth: A strategic guide for US pharma innovators
1+ week, 5+ day ago (730+ words) Artificial intelligence (AI) is quietly reshaping pharmaceutical research. Driven by promises of faster trial design and drug discovery, the global AI-in-pharma market is projected to grow over 40% annually through 2030. Yet, for US drug developers, bringing these tools across the Atlantic…...
The strategic opportunity: Owning the behaviour layer
2+ week, 3+ day ago (1596+ words) In the third and final part of this longevity series, I discuss how science discovers what extends life. Healthcare treats its failure, too late. In between these two sits the layer where outcomes are actually determined: daily behaviour. This is…...